ResMed today has completed the acquisition of Ectosense, makers of the NightOwl cloud-connected home sleep test (HST).
Ectosense’s FDA-approved NightOwl is sold in the United States, Australia, New Zealand, India, and parts of Europe. ResMed has distributed NightOwl in Australia and India since 2020 under the brand “ResMed onesleeptest,” and has been a minority investor in Ectosense since July 2020. A ResMed spokesperson notes in an email to Sleep Review that the NightOwl disposable HST is consumer-friendly because “it is digital and easy to use in lab or at home.”
ResMed will continue to sell its ResMed ApneaLink Air home sleep test device; “it’s enabled sleep labs, doctors, and other clinicians to process over 1.5 million diagnostic sleep tests in the cloud,” according to the ResMed spokesperson.
“Sleep labs and home tests each have critical roles to play in expanding our reach and identifying the 936 million people worldwide who have sleep apnea,” says Jim Hollingshead, ResMed president of Sleep & Respiratory Care, in a release. “We believe Ectosense’s digital and easy-to-use solutions in the hands of both sleep lab technicians and consumers worldwide can help significantly increase diagnoses, as well as general awareness of this highly prevalent, 100% treatable disease. For millions of people, their best night’s sleep must start with a diagnosis.”
ResMed plans to focus on scaling up in the regions where ResMed sells NightOwl today and will continually assess other opportunities.
Justin Leong, ResMed president of Asia and Latin America, says in a release, “In developing markets, we need to make sleep tests affordable, accessible and easy to use. Ectosense’s clinically validated, consumer-friendly devices will enable us to help millions of people in many markets improve their sleep and overall health. We’re excited to welcome Ectosense’s life-changing team to the ResMed family.”
Frederik Massie, chief technology officer and cofounder of Ectosense, says in a release, “ResMed has the global reach and passionate ambition to help increase patient access to Ectosense’s proven diagnostic solution and a path to better sleep and overall health. It will take the combined efforts of sleep labs and connected home solutions like NightOwl to identify a significant portion of the hundreds of millions of people suffering from this disease that don’t even know it.”
Ectosense will operate within ResMed’s Sleep and Respiratory Care business. The transaction is not material to ResMed’s consolidated financial results; its financial terms were not disclosed.